BPC-157 vs TB-500: the 2026 research peptide comparison for tissue regeneration and repair BPC-157 vs TB-500: two research stars in tissue repair Two peptides have dominated research on musculotendinous regeneration, intestinal healing and vascular repair for a decade: BPC-157 (Body Protection Compound 15 amino acids, derived from a human gastric protein) and TB-500 (active 17-mer fragment of endogenous Thymosin -4)
GLP-1 agonists may be the newest entrant in that category, with one crucial advantage over the others: they have massive Phase 3 safety and efficacy datasets in humans
KovcsZD'AgostinoDPDiamondDMAriC
These results suggest even healthy individuals should be cautious with aspirin use, as it may result in gastrointestinal barrier dysfunction
For cagrilintide specifically, the coming years will determine whether its distinct mechanism can carve out a meaningful roleeither as a standalone therapy through the RENEW program or as part of combination approaches like CagriSema and potentially future pairings Other questions about cagrilintide Because cagrilintide is still in clinical development, many common questions relate to its availability, safety, and how it compares with existing medications
